3Allou N,Piednoir P, Berrota C, et al. Incidence and risk factors of early thromboembolic events after mechanical heart valve replacement in patients treated with intravenous unfractionated heparin[J]. Heart, 2009,95 (20) 1694-- 1700.
4Whitlock RP, Sun JC, Fremes SE, et al. Antithrombotic and thrombolytic therapy for valvular disease antithrombotic ther- apy and prevention of thrombosis, 9th ed: american college of chest physicians evidence- based clinical practice guidelines [J]. Chest, 2012,141 .. 576--600.
2Fenstad ER, Le RJ, Sinak LJ, et al. Pericardial effusions in pul- monary arterial hypertension characteristics, prognosis, and role of drainage[J]. Chest, 2013,144(5) : 1530- 1538.
3Halpern DG, Argulian E, Briasoulis A, et al. A novel pericardial ef{usion scoring index to guide decision for drainage[J]. Crit Pathw Cardiol, 2012,11 ( 2 ) : 85 - 88.
5Hendriks JML, de Wit R, Crijns HJGM, et al. Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation [J]. Eur Heart J,2012,33(21) :2692-2699.
6Van Damme S, Van Deyk K, Budts W, et al. Patient knowledge of and adherence to oral anticoagulation therapy after mechani- cal heart-valve replacement for congenital or acquired valve defectsEJ-. Heart Lung,2011,40(2): 139-146.
7Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease[J]. JACC, 2006,48(3): 146- 148.
8Rick AN,Blase AC,David PF,et al. 2008 focused update incor- porated into the ACC/AHA 2006 guidelines for the manage-ment of patients with valvular heart disease[J]. JACC, 2008, 52(13): 140-142.
9Kim JH, Kim GS, Kim EJ, et al. Factors affecting medication adherence and anticoagulation control in korean patients taking warfarin[J]. J Cardiovasc Nurs, 2011,26 (6):466- 474.
